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Background: China is approaching measles elimination, but indigenous measles still circulates. County L in China
has reported measles-containing vaccine (MCV) coverage rates >95% since 2000. Despite high reported coverage, a
large measles outbreak occurred among young children in L County. We measured MCV coverage using 5 different
methods during an investigation on this outbreak and compared our estimates with reported rates.
Methods: Reported coverage rates are determined by aggregating clinic-based data across the county: doses
administered in each clinic divided by the number of children registered in each clinic. Our methods estimated
coverage for the 2010–2012 birth cohort, and were (1) administrative method: doses administered in clinics divided
by the birth cohort recorded in the Statistical Year Book, (2) house-to-house convenience-sample survey of children
living near cases, (3) vaccination clinic records review, (4) determination of a convenience sample of measles
outbreak cases’ vaccination statuses and using the field vaccine efficacy outbreak equation to estimate population
coverage, and (5) a seroprevalence survey using a convenience sample of residual blood samples from hospitals.
Results: The measles outbreak totaled 215 cases, representing an incidence of 195.8 per million population. Our
estimated MCV coverage rates were: (1) administrative method: 84.1%-87.0% for MCV1 and 80.3%-90.0% for MCV2,
(2) in-house survey: 83.3% of 9–17 month children received MCV1, and 74.5% of 24–47 month children received
MCV2, (3) clinic record review: 85.5% of 9–17 month children received MCV1, and 73.2% of 24–59 month children
received MCV2, (4) field VE method: 83.6% of 9–47 month children received one or more MCV doses, and
(5) serology: seropositive rates were <80% in the 12–17 and 18–23 month age cohorts.
Conclusions: Compared with reported coverage >95%, our 5 coverage assessments all showed substantially lower
coverage. China should evaluate guidelines for reporting vaccination coverage and identify feasible improvements
to the assessment methods.
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The World Health Organization Western Pacific Region
has been striving to eliminate measles since 2005 [1] and
set a goal to eliminate measles in the region by 2012.
China adopted this goal and endorsed an action plan for
measles elimination in 2006 that included continuing a
two-dose measles-containing vaccine (MCV) strategy (ad-
ministered at 8 months and 18–23 months of age), and
called for routine measles vaccine coverage to be greater
than 95% for both doses in every county, while using sup-
plementary immunization activities (SIAs) to close im-
munity gaps among children [2].
Between 2004 and 2009, 27 of the 31 mainland prov-
inces conducted unsynchronized province-wide measles
SIAs targeting children aged 8 months through 14 years.
In September 2010, China conducted a synchronized na-
tionwide SIA targeting different age groups by province;
children were vaccinated regardless of their prior vaccin-
ation status. Using the combined province-wide catch-up
SIAs and nationwide follow-up SIA strategy, each prov-
ince had covered their 1995–2009 birth cohorts through
SIAs by 2010.
With these efforts, the measles incidence of China de-
creased dramatically, from 99.4 per million population in
2008 to 4.6 in 2012. However, indigenous measles virus
outbreaks have been continuously reported, and a resur-
gence occurred in the end of 2012 that continued into
2013. Between January and October 2013, there were over
26,000 measles cases reported in China, which was 1.7
times more than case number of the same time period in
2011 and 4.6 times more than that in 2012. Of these cases,
68% were among children under 5 years of age [3], raising
the concern that timely, 2-dose MCV coverage may not be
high enough to eliminate measles outbreaks among young
children.
In China, all vaccines are delivered through a public in-
frastructure with vaccination clinics and fixed-sites in
urban and rural areas, and are offered to local children
and to children new to the area who have registered for
clinic services. Clinic immunization providers record each
dose of vaccine administered, either through a vaccination
card or a computerized immunization information system.
Children who receive any routine vaccination in the clinics
are registered in the clinic. Clinics are required to report
vaccination coverage levels by dividing the number of chil-
dren vaccinated in the clinics by the number of children
registered in clinics. Reported coverage measured with this
method has consistently been >98% in China [4,5], how-
ever, these rates may be too high because children not reg-
istered in a clinic are not included in the denominator.
Survey-based coverage estimates in China have been lower
than reported coverage. For example, a 2009 estimate
showed coverage to be 91.1% for MCV1 and 84.3% for
MCV2 [2]. A national coverage survey was conducted in2011, using a stratified cluster sampling to select counties
and Probability Proportional to Size sampling to select ob-
jects. Of the 4,681 children randomly sampled from 32
counties, 160 townships, and 480 villages, coverage rates
for MCV1 and MCV2 were 99.4% and 93.35%, respect-
ively [6].
In February 2013, a measles outbreak was reported in L
County of Hu Nan province, with 215 measles cases,
representing an incidence of 195.8 per million population.
This county has reported administrative coverage of MCV
greater than 95% since 2000. As a part of the province-
wide catch up SIA in April 2009, L County targeted 8-
month through 14-year-old children (birth cohorts of
1994 through part of 2008), and reported 98% coverage.
As part of the 2010 nation-wide campaign, L County tar-
geted 8-month through 4-year-old children (birth cohorts
between October 2005 and 2009) and reported 98% cover-
age. Among all cases reported in the 2013 outbreak, 88%
were among ≤3 year old children, and only 22% of 8–47
months old cases had received at least 1 MCV dose. The
disease pattern raised our concern that there may be a dis-
crepancy between reported and real MCV coverage rates.
The investigation of this outbreak provided an oppor-
tunity to determine whether coverage was as high as had
been reported. We used 5 qualitatively different methods
to estimate MCV coverage or protection levels in L
County. We report the results of these measurements
and contrast them to the reported coverage rates.
Methods
Case-based measles surveillance data were obtained from
the National Measles Surveillance System. A suspected
measles case was defined using World Health Organization
(WHO) criteria as a person with fever, rash, and one or
more of the following symptoms: cough, coryza, or con-
junctivitis. Key variables obtained included age, sex, ad-
dress of residence, date of onset, occupation, MCV
vaccination history, and measles-specific immunoglobulin
(IgM) testing results. Case data were analyzed to describe
person, place and time characteristics of the outbreak.
During the field investigation, additional data were col-
lected to estimate measles vaccine coverage and popula-
tion susceptibility by using the following five methods.
Administrative data coverage estimate
Routine immunization MCV1 and MCV2 coverage of the
birth cohorts born after the 2010 measles SIA were esti-
mated by using data from L County. The number of
MCV1 and MCV2 doses administered through routine
immunization in L County clinics in 2010, 2011 and 2012
were used as numerators, and the published data on num-
ber of new births reported in the Statistical Year Book for
L County as denominators. Because this method is eco-
logic, the number of MCV2 doses can exceed the number
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method differs from the reported coverage method in the
denominator – the reported coverage uses children regis-
tered in clinics, while this administrative data coverage es-
timate uses recorded births.
House-to-house coverage survey
During the measles outbreak investigation, we identi-
fied a sample of children who had not acquired measles
but who lived near a convenience sample of the mea-
sles cases. Investigators started from the house closest
to the residence of each case, and visited additional
houses one-by-one in a random direction to search for
three healthy children of the same age as the case. In-
vestigators reviewed vaccination certificate cards, and
obtained records of each dose of MCV administered. If
the certificate card was not available during in-house
visit, investigators checked the immunization records
in the vaccination clinic. In total, 190 parents of chil-
dren aged 9 months to 15 years old were interviewed
and their children’s vaccinations recorded.
Immunization clinic records review
In the 9 townships of L County with the most measles
cases reported, investigators reviewed clinic-registered
children’s vaccination records. Records from a minimum
of 40 children, 9–59 months old (birthdate between 1
January 2008 and 31 March 2012), were randomly se-
lected from each township clinics’ list of registered chil-
dren, and all MCV doses administered were recorded
for each child.
Coverage estimation by vaccine efficacy equation
In the 1980s, Orenstein and colleagues developed an equa-
tion to determine vaccine efficacy (VE) in the field during
an outbreak [7]. The equation is PCV = (PPV − (PPV*VE))/
(1 − (PPV*VE)), where PCV is the proportion of cases vac-
cinated; PPV is the proportion of the population vacci-
nated; and VE is vaccine efficacy. PPV (coverage) can be
calculated if PCV is known and the vaccine has a known,
relatively constant VE. We estimated MCV coverage of 9–
47 months old children using the algebraic transformation
of the field VE equation: PPV = PCV/(1 − VE(1 − PCV))
[7,8]. In this calculation, we assumed efficacy of a single-
dose of measles vaccine to be 90%, and we assumed that
the vaccination rate in case-patients with unknown vac-
cination history was the same as in case patients with
known vaccination history [8].
Prevalence of measles antibodies study
There are 2 major hospitals in L County, and in March
2013, we obtained residual serum specimens from these
2 hospitals’ clinical laboratories. Specimens were from
non-fever, non-rash ill patients less than 35 years old.The specimens were shipped to Hu Nan Provincial CDC
for measles-specific IgG testing to determine susceptibil-
ity to measles. The commercial Virion\Serion ELISA kit
was employed to detect and quantify human IgG anti-
bodies against measles virus in the sera. The laboratory
results were interpreted according to the manufacturer’s
instructions. Titers ≥1:200 were considered positive and
titers <1:150 were considered negative. Sera samples for
which the results were equivocal were retested using the
same method; if again equivocal, we considered the re-
sult negative. Demographic information including age,
gender, and location of residence were obtained, but
individual-identifying data and immunization status and
history of measles infection were not obtained. These
data were analysed after determining sero-positivity and
geometric mean titer.Ethical review considerations
Individual identifying information on the persons whose
blood was tested for measles antibodies was not obtained
by the investigators; the individuals were not contacted or
interviewed; and informed consent was therefore not
obtained. Obtaining and testing these samples of
residual blood was approved by the Ethical Review
Committee of Chinese Center for Disease Control and
Prevention (Approval Notice No. 201410), recognizing that
the right and the welfare of the subject are adequately pro-
tected; the potential risks are outweighed by potential ben-
efits. Administrative (doses administered) data, coverage
survey data, and vaccination record review data that are
collected as part of a vaccine preventable disease outbreak
investigation are considered by China CDC’s Ethical Re-
view Committee to be exempt from IRB review. Informed
consent is not obtained for accessing administrative, sur-
vey, and immunization clinic record data. Individual iden-
tifying data were not retained in analytic data sets.Results
Outbreak description
A total of 215 measles cases were identified in 24 of 26
townships in L County; 209 were laboratory confirmed
and 6 were epidemiologically linked to a laboratory
confirmed case. Of these, 153 cases (71.2%) were male,
representing incidence (per million population) of 243.9
for male and 107.1 for female in this county. The out-
break started on January 9 and ended on June 19, 2013
(Figure 1). Of the 215 cases, 189 cases (87.9%) were
born after 1 January 2010 and therefore had not been
part of the 2010 nationwide measles campaign; 16 cases
(7.4%) were born between 1 October 2005 and 31 Decem-
ber 2009 and were part of the 2010 nationwide campaign
target age group; and 10 cases (4.6%) were >15 years old
(Figure 2).
Figure 1 Weekly distribution of reported measles cases, 2008-November 2013, L County, Hu Nan province, China.
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From 2010 through 2012, the annual number of doses of
MCV1 delivered through routine immunization in L
County ranged between 13,718 and 14,452 doses, and the
annual number of MCV2 doses ranged between 13,874
and 14,711 doses. Officially reported administrative cover-
age data for both MCV1 and MCV2 were >99% (Table 1).
The number new births in 2010 to 2012 reported in
the Statistical Year Book ranged between 16,235 and
16,857. The calculated coverage estimate using the above
doses administered data as the numerator and reportedFigure 2 Birth-date distribution of the 215 measles cases reported inbirths as the denominator in 2010 through 2012 in L
County ranged from 84.1% to 87.0% for MCV1, and
from 80.3% to 90.0% for MCV2 (Table 1).
For the house-to-house survey, investigators inter-
viewed 186 parents of children aged 9–179 months. Of
72 children aged 9–17 months who were age-eligible for
MCV1, 83.3% (95% CI: 72.7-91.1) had received the first
dose. Of 28 children between 18 and 23 months of age
and eligible for MCV2, 85.7% (95% CI: 67.3-96.0) re-
ceived MCV1, and 32.1% (95% CI: 15.9-52.4) received
MCV2. Among 51 children 24–47 months old and dueL County, Hu Nan province.
Table 1 Estimated MCV routine immunization coverage during 2010–2012, L County, Hu Nan province, China
Year Dose Reported coverage Administrative estimated coverage
Number of vaccinated‡ Number of target† Reported coverage (%) Number of new birth cohort Estimated coverage (%)
2010 MCV1 14452 14526 99.5 16613 87.0
MCV2 14657 14740 99.4 16725 87.6
2011 MCV1 13718 13728 99.9 16235 84.5
MCV2 14711 14722 99.9 16354 90.0
2012 MCV1 14182 14193 99.9 16857 84.1
MCV2 13874 13886 99.9 17267 80.3
‡The number of MCV2 doses can exceed the number of MCV1 doses when children change clinics.
†The “number of target” here, is the total number of children who have registered, and received routine immunization in vaccination clinics. It’s the denominator
of administrative coverage.
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74.5% (95% CI: 60.4-85.7) received MCV2. All 35 children
over 48 months old had received MCV2 (Table 2).
In L County immunization clinics, 365 children’s immu-
nization records were identified at random and were
reviewed. Among 69 children aged 9–17 months, 85.5%
(95% CI: 75.0-92.8) received MCV1. Among 46 children
aged 18–23 months (eligible for MCV2), all received
MCV1, and 41.3% (95% CI: 27.0-56.8) received MCV2.
Among the 250 children aged 24–59 months, 73.2% (95%
CI: 67.3-78.6) received MCV2 (Table 3).
For the VE equation method, we obtained MCV vac-
cination status for 108 measles cases aged 9–47 months
who were reported in the outbreak. Among these, 22
(20.4%) had received ≥1 dose MCV, while 86 (79.6%)
had received no MCV doses. Using these rates to deter-
mine the proportion of cases vaccinated, and assuming
90% VE for one dose of measles vaccine, the vaccination
coverage for this age group was estimated with the field
VE equation to be 83.6%.
Prevalence of measles antibodies
In total, 632 residual serum specimens were tested for
measles IgG antibodies, and 74.5% (95% CI: 70.9-77.9) of
these samples tested positive. Seropositive rates de-
creased from 60.0% (95% CI: 45.2-73.6) in 0–1 month
group to 18.2% (95% CI: 5.2-40.3) in the 6–7 month age
group. Seropositivity increased starting with the 8–9
months group and reached 90.1% (95% CI: 82.1-95.4) in
the 24–47 month age group. Children 48 months to 15Table 2 Coverage assessment from in-house interview, L Cou
Age group
(months)
No. of children by MCV doses
0 doses 1 dose ≥2 doses
9-17 12 59 1
18-23 4 15 9
24-47 1 12 38
48-179 0 0 35
Total 17 86 83years old had the highest seropositive rate, which was
95.8% (95% CI: 90.5-98.6). The 12–17 month and 18–23
month groups had seropositive rates less than 80%.
GMT titers for each age group showed similar trends as
the seropositive rate (Table 4).
Discussion
We have shown that reported MCV coverage, which is
determined using clinic-registered children as the de-
nominator, yields a higher coverage estimate than 5
qualitatively different coverage assessment methods
that were obtained during a measles outbreak investiga-
tion. Because officially reported coverage estimates in
China do use clinic-registered children as the denomin-
ator, reported coverage is likely to be higher than actual
coverage. This higher-than-actual reported coverage
may provide a partial explanation why indigenous cir-
culation of measles has continued in China despite
more than 25 years of a 2-dose MCV vaccination pol-
icy, the strategy of using measles SIAs, and high re-
ported coverage with MCVs.
Conducting SIAs is useful to address coverage inequities
and rapidly close population immunity gaps in targeted
age groups. This has been demonstrated both in China
and elsewhere in the world [9-12]. However, SIAs should
not be considered superior to routine immunization [13],
because they provide vaccination in an intermittent man-
ner, allowing for accumulation of susceptible children be-
tween campaigns. Experience from previous elimination
programs has demonstrated that a 2-dose measles vaccinenty, Hu Nan province, China, 2013
Proportion of ≥1
doses (%, 95% CI)
Proportion of ≥2
doses (%, 95% CI)Total
72 83.3 (72.7-91.1) -
28 85.7 (67.3-96.0) 32.1 (15.9-52.4)
51 98.0 (89.5-99.9) 74.5 (60.4-85.7)
35 100 100
186 90.9 (85.8-94.6) -
Table 3 MCV immunization status for the 365 registered children, L County, Hu Nan province, China, 2013
Age group
(months)
Number of children (No., %) Coverage (%, 95% CI)
0 doses 1 dose 2 doses Total ≥1 dose ≥2 doses
9-17 10 54 5 69 85.5 (75.0-92.8) -
18-23 0 27 19 46 100.0 (92.3-) 41.3 (27.0-56.8)
24-59 2 65 183 250 99.2 (97.1-99.9) 73.2 (67.3-78.6)
Total 12 146 207 365 96.7 (94.3-98.3) 56.7 (51.5-61.9)
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taining measles elimination status [14-16]. In the United
States, there have been three efforts to eliminate measles
targeting 1967, 1982, and 1996. Over the years, the U.S.
experienced several failures, but systematically incorpo-
rated the lessons learned from each failure into subse-
quent efforts, and finally achieved the goal in 2000 [17,18].
Key lessons learned from the efforts include: (1) elimin-
ation requires very high MCV vaccination coverage by age
2 years, (2) a second dose of measles vaccine is needed to
achieve satisfactory levels of immunity, and (3) coverage
assessment is crucial [17,19].
In this outbreak, the 2010–2012 birth cohorts, which
became age-eligible for measles vaccination following
the 2010 campaign, had the highest incidence of mea-
sles. Fully 80% of the 108 MCV-eligible cases were un-
vaccinated. This pattern raised our interest in providing
alternative estimates of true coverage as a check on the
high reported coverage that was calculated using doses
administered data with clinic-registered children as the
denominator. Each result of the five independent meas-
urement methods revealed that coverage of 2010, 2011,
and 2012 birth cohorts was below 85%, which is much
lower than the 95% target objective needed to eliminate
measles, and much lower than coverage that was offi-
cially reported.Table 4 Sero-prevalence of measles by age group,










0-1 50 30 60.0 (45.2-73.6) 163.05
2-3 37 15 40.5 (24.8-57.9) 163.23
4-5 34 10 29.4 (15.1-47.5) 43.27
6-7 22 4 18.2 (5.2-40.3) 27.07
8-9 20 5 25.0 (8.7-49.1) 34.25
10-11 27 10 37.0 (19.4-57.6) 38.9
12-23 71 54 76.1 (64.5-85.4) 360.16
24-47 91 82 90.1 (82.1-95.4) 822.43
48-179 120 115 95.8 (90.5-98.6) 914.99
180-419 160 146 91.3 (85.8-95.1) 743.84
Total 632 471 74.5 (70.9-77.9) 359.45Several recently-published and unpublished studies
also showed that low coverage of new birth cohorts after
the 2010 campaign was a key factor contributing to
China’s measles resurgence [8]. These outbreaks were
due to failure to provide measles vaccine for children at
recommended ages. Although the 2011 national survey
showed high coverage for both MCV1 and MCV2 at the
national level, low-coverage areas were also identified in
the survey [5], indicating that “pocket areas” exist. A
recently-published coverage survey also showed that
coverage among a migrating population was lower than
among local populations [20].
To eliminate measles in China, learning from other
elimination programs and from domestic measles out-
breaks is critically important. Several strategies are import-
ant for China. First, increasing and maintaining high
(≥95%) coverage of both MCV1 and MCV2 through rou-
tine immunization is the top priority at this stage. The
1996–2009 birth cohorts (in some provinces back to the
1990 birth cohorts) have been targeted by SIAs, and many
fewer cases have been reported from these age-group since
2011 [21]. The majority of new, potential susceptibles will
come from new born children. Maintaining high coverage
through routine immunization can minimize the number
of susceptibles, and consequently avoid periodic epi-
demics. China is undergoing a large urban migration, lead-
ing to over 236 million migrant workers in 2012 [22],
which complicates the administration of vaccines given in
series and given during times of family movement. Con-
ducting outreach to migrant children becomes an add-
itional need for closing immunity gaps.
Second, delivering both MCV1 and MCV2 to 8-
month and 18-month old children on time is essential.
Several studies indicated that children born to vacci-
nated mothers lose their maternal antibodies earlier
than children whose mothers were immune through in-
fection [23-25]. Seroprevalence data from this study
also showed the trend of rapidly decreasing seropreva-
lence - from 60% in 0–1 months to the lowest level of
18.2% in infants 6–7 months of age. China provides
MCV1 at one of the youngest ages globally – 8 months.
This young age is designed to protect children as early
as possible, prior to risk of getting infection. To avoid
future outbreaks, it is crucial to attain high coverage
levels by timely vaccination [20], so that herd immunity
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vaccinate.
Third, frequent monitoring of coverage is important to
identify program areas that need to be strengthened. Out-
breaks of measles can also be used to find program weak-
nesses, but outbreaks are lagging indicators. In contrast,
coverage can be a leading indicator to find areas in need of
additional effort before an outbreak occurs [17]. The un-
realistically high coverage reported is not consistent with
China’s current measles epidemiology. Having higher-
than-actual reported coverage can undermine confidence
in vaccination strategies by giving false sense that the
programme cannot improve coverage, and may lead to a
lack of understanding why outbreaks are occurring.
Fourth, coverage assessments should strive to include
all children in an area. A purpose of coverage measure-
ment is to identify areas at risk of disease outbreaks. It
would not have been possible to use reported coverage
to predict the L County outbreak because reported
coverage ranged from 99.4% to 99.9% for each of the
birth cohorts affected by the outbreak. Most likely, the
restriction of the denominator to clinic-registered chil-
dren resulted in missing children in the area who should
have been registered in the clinic and vaccinated. Given
the large urban migration in China, including all chil-
dren in an area in coverage assessments will be an im-
portant component in an effective measles elimination
strategy. When a measles outbreak occurs in a commu-
nity, an initial step for public health officials can be to
use population estimates to determine whether the num-
ber of children registered in community clinics is consist-
ent with population estimates. If inconsistent, community
based surveys using rigorous methodology may be indi-
cated [26].
Fifth, enhancing outbreak analysis and response activ-
ities to close immunity gaps will be needed to eliminate
measles. Given the imbalance of socioeconomic deve-
lopment and immunization program capacity, small area
SIAs are likely to be needed as a supplement to routine
immunization in less developed areas. These SIAs depend
on the epidemiology of measles and identification of im-
munity gaps. Surveillance and outbreak analysis can pro-
vide additional information to determine the extent to
which missed opportunities to vaccinate occur, and then
decide which types of actions should be taken [27].
Limitations
This study has several limitations, primarily the limita-
tions of each of the 5 methods. The administrative
method used Statistical Year Book birth records, and
therefore would miss in- and out-migration among
young children. The house-to-house survey is a con-
venience sample of neighborhood- and age-matched
children, and is not representative of the entire county.Since these children did not get measles despite living
near cases, their coverage may have been higher than
the county average. The clinic review will miss children
who never registered with the clinic, and can include
children who moved away from the area. The VE equa-
tion method relies on the stability of the VE estimate.
The serological survey was a convenience sample of
children seen in the 2 hospitals, and previous studies
comparing commercially available EIA assay versus the
gold standard plaque reduction–neutralization assay
have demonstrated that EIA was less sensitive, but is a
reliable identifier of measles-seronegative individuals
[28]. Although each of the 5 methods used in this study
is imperfect and has advantages and disadvantages, all
the 5 results come to the same conclusion that actual
coverage is lower than reported coverage that is deter-
mined with a clinic-based denominator. We feel that a
key strength of this study is the convergence of results
from 5 qualitatively different methods. We therefore
believe that our conclusion is supported by the evi-
dence provided.
Recommendation
We recommend review and evaluation of the methods for
estimating officially-reported vaccination coverage levels in
China, with a goal of identifying feasible coverage assess-
ment methods that will provide useful information for the
immunization program in China. Methods that include
children not registered in immunization clinics should be
sought.
Conclusions
The L County measles outbreak was due to low routine
immunization coverage, which was inconsistent with the
high coverage rates that had been reported before the out-
break. Despite very high reported administrative coverage,
measles epidemics will occur as a result of actual low vac-
cine coverage in socio-demographically clustered, mainly
unvaccinated communities that accumulate susceptibles
in new birth cohorts. Improving coverage assessments
to identify areas of low coverage in time to prevent out-
breaks will help the program achieve the goal of elimin-
ating measles.
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